Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 09 Nov 2023
What next for PHARMAC boss after 'sick, sneering' remarks about Rachel Smalley?
10 November 2023 - PHARMAC’s CEO has managed to survive scrutiny from her board over sneering remarks made about broadcaster ...
Posted by Michael Wonder on 09 Nov 2023
Getting ready for EMA’s website relaunch on 5 December 2023
9 November 2023 - The EMA is relaunching its corporate website on 5 December 2023. ...
Posted by Michael Wonder on 09 Nov 2023
UnitedHealth unit to add eight insulin products to its reimbursement list
9 November 2023 - UnitedHealth's pharmacy benefit manager unit said on Thursday it was adding eight insulin products to its ...
Posted by Michael Wonder on 09 Nov 2023
FDA approves first treatment for patients with rare inherited blood clotting disorder
9 November 2023 - Today, the US FDA approved Adzynma, the first recombinant protein product indicated for prophylactic or on demand ...
Posted by Michael Wonder on 09 Nov 2023
FDA amends pembrolizumab’s gastric cancer indication
9 November 2023 - On 7 November 2023, the FDA revised the existing indication of pembrolizumab (Keytruda, Merck) with trastuzumab, fluoropyrimidine, ...
Posted by Michael Wonder on 09 Nov 2023
CASI Pharmaceuticals announces market approval of CNCT19 by China NMPA
8 November 2023 - CASI Pharmaceuticals is thrilled to announce a major milestone in its partnership with Juventas Cell Therapy. ...
Posted by Michael Wonder on 09 Nov 2023
US FDA accepts for priority review Bristol Myers Squibb’s application for Breyanzi (lisocabtagene maraleucel) for relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma
9 November 2023 - Application based on results from TRANSCEND CLL 004, the first pivotal multi-centre trial to show clinical benefit ...
Posted by Michael Wonder on 09 Nov 2023
MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss
8 November 2023 - For the first time in the UK, obese patients and people who are overweight with weight-related health ...
Posted by Michael Wonder on 09 Nov 2023
Vanflyta approved in the EU as the first FLT3 inhibitor specifically for patients with newly diagnosed FLT3-ITD positive AML
9 November 2023 - Approval based on QuANTUM-First results demonstrating Vanflyta added to chemotherapy improved overall survival. ...
Posted by Michael Wonder on 09 Nov 2023
Same drug, two prices: why the higher price prevails
8 November 2023 - Patients are paying hundreds of dollars more for a prescription than they would if their health plan ...
Posted by Michael Wonder on 09 Nov 2023
HHS considers removing J&J’s Stelara from Medicare drug price negotiations
7 November 2023 - The Department of Health and Human Services in a supplemental court filing posted late last week ...
Posted by Michael Wonder on 09 Nov 2023
FDA’s Califf wants to get the public as excited about life expectancy as cures
8 November 2023 - It’s easy to get people worked up about cures, but they don’t seem to be bothered ...
Posted by Michael Wonder on 09 Nov 2023
Takeda receives US FDA approval of Fruzaqla (fruquintinib) for previously treated metastatic colorectal cancer
8 November 2023 - Fruzaqla is the first targeted therapy approved for metastatic colorectal cancer regardless of biomarker status or ...
Posted by Michael Wonder on 09 Nov 2023
Paddy Gower has issues: blind, solo mum desperate for PHARMAC to fund life-changing medicine so she can see her kids
8 November 2023 - We sat in a field of wild daisies. Bright white and yellow against a backdrop of ...
Posted by Michael Wonder on 09 Nov 2023
PHARMAC asked to reconsider funding RSV drug for at risk babies
9 November 2023 - Paediatricians and neonatal experts are pleading with PHARMAC to rethink its decision to stop funding a ...